Latest News for: caution xenon

Edit

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024

Enid News & Eagle 08 Jan 2024
08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... Xenon’s XEN1101 Phase 3 epilepsy program includes two identical Phase 3 clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase 2b X-TOLE clinical trial.
Edit

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of ...

The Eagle-Tribune 02 Dec 2023
02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... Xenon is also presenting pre-clinical work from its discovery efforts related to the exploration of Nav1.1 potentiators for the treatment of Dravet Syndrome.Poster No ... Xenon Pharmaceuticals Inc.
Edit

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical ...

Enid News & Eagle 27 Nov 2023
27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... Xenon will host a conference call and webcast today at 8.30 am Eastern Time to discuss the Phase 2 X-NOVA results ... About Xenon Pharmaceuticals Inc ... Xenon Pharmaceuticals Inc.
Edit

Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences

The Eagle-Tribune 10 Nov 2023
09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... About Xenon Pharmaceuticals Inc ... For more information, please visit www.xenon-pharma.com ... “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc.
Edit

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Enid News & Eagle 08 Nov 2023
08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... Xenon’s XEN1101 Phase 3 epilepsy program includes two identical Phase 3 clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase 2b X-TOLE clinical trial.
Edit

Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical ...

The Eagle-Tribune 09 Oct 2023
09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... About Xenon Pharmaceuticals Inc ... For more information, please visit www.xenon-pharma.com ... “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc.
Edit

Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

The Eagle-Tribune 04 Sep 2023
04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... On Sunday, September 3, 2023, Xenon hosted the following presentations at IEC 2023.Poster ... About Xenon Pharmaceuticals Inc ... For more information, please visit www.xenon-pharma.com.
Edit

Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Eagle-Tribune 09 May 2023
VANCOUVER, British Columbia, May 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... Given the prioritized focus on the pediatric development plans for XEN1101, Xenon will no longer pursue the clinical development of XEN496.
Edit

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at theAnnual ...

Eagle-Tribune 02 Dec 2022
02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... Ian Mortimer, Xenon’s President and Chief Executive Officer stated, “We continue to advance our portfolio of neurology-focused programs ... Xenon’s Scientific Exhibit and Booth.
Edit

Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Eagle-Tribune 08 Nov 2022
08, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We have made significant progress during the past quarter to support the initiation of our XEN1101 Phase 3 program.
Edit

Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program

Kentucky New Era 22 Jun 2022
BURNABY, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... About Xenon Pharmaceuticals Inc ... For more information, please visit www.xenon-pharma.com ... Jodi Regts Xenon Pharmaceuticals Inc ... investors@xenon-pharma.com.
  • 1

Most Viewed

×